Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 701–800 of 1,060

Cellular Consequences of the Association of ApoB Lipoproteins With Proteoglycans
Hurt‐Camejo, E., Olsson, U., Wiklund, O., Bondjers, G., & Camejo, G. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.6.1011 · Cited by 165
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Ethnic differences of the presence and severity of coronary atherosclerosis.
Budoff, M., Nasir, K., Mao, S., Tseng, P. H., Chau, A., Liu, S., Flores, F., & Blumenthal, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.013 · Cited by 172
Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia
Matsuzaki, M., Hiramori, K., Imaizumi, T., Kitabatake, A., Hishida, H., Nomura, M., Fujii, T., Sakuma, I., Fukami, K., Honda, T., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01955-1 · Cited by 165
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks, D., Wonderling, D. E., Thorogood, Lambert, Humphries, S. E., & Neil (2000) · Health Technology Assessment · doi:10.3310/hta4290 · Cited by 163
Markers of inflammation and their clinical significance
Ballantyne, C. M., & Nambi, V. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.02.005 · Cited by 168
Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
Goldman, D. P., Joyce, G., & Karaca‐Mandic, P. (2006) · PubMed · Cited by 163
Clinical Pharmacokinetics of Fluvastatin
Scripture, C. D., & Pieper, J. A. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00003 · Cited by 165
Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris
Boven, A. J. V., Jukema, J. W., Zwinderman, A. H., Crijns, H. J. G. M., Lie, K. I., & Bruschke, A. V. G. (1996) · Circulation · doi:10.1161/01.cir.94.7.1503 · Cited by 163
Heart Attacks: Gone with the Century?
Brown, M. S., & Goldstein, J. L. (1996) · Science · doi:10.1126/science.272.5262.629 · Cited by 163
Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 160
Androgenic Anabolic Steroid Abuse and the Cardiovascular System
Vanberg, P., & Atar, D. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79088-4_18 · Cited by 171
Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey
Primatesta, P., & Poulter, N. R. (2000) · BMJ · doi:10.1136/bmj.321.7272.1322 · Cited by 161
Cholesterol lowering and endothelial function
Vogel, R. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00261-2 · Cited by 160
Primary Prevention With Statins in the Elderly
Mortensen, M. B., & Falk, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.080 · Cited by 164
Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice
Vecchione, C., & Brandes, R. P. (2002) · Circulation Research · doi:10.1161/01.res.0000028004.76218.b8 · Cited by 160
Differential Effects of Lipid-Lowering Therapies on Stroke Prevention
Corvol, J., Bouzamondo, A., Sirol, M., Hulot, J., Sanchez-Peña, P., & Lechat, P. P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.669 · Cited by 162
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160
Incidence of cancer and statin usage—Record linkage study
Haukka, J. K., Sankila, R. J., Klaukka, T., Lönnqvist, J. K., NISKANEN, L. K., Tanskanen, A. J., Wahlbeck, K., & Tiihonen, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24536 · Cited by 163
Perioperative Management of Chronic Heart Failure
Groban, L., & Butterworth, J. F. I. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000226099.60493.d9 · Cited by 159
Role of Endothelial Dysfunction in Coronary Artery Disease and Implications for Therapy
Kinlay, S., & Ganz, P. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00793-5 · Cited by 160
The antiatherogenic role of high-density lipoprotein cholesterol
Kwiterovich, P. O. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00808-x · Cited by 158
Predominance of Dense Low-Density Lipoprotein Particles Predicts Angiographic Benefit of Therapy in the Stanford Coronary Risk Intervention Project
Miller, B. D., Alderman, E. L., Haskell, W. L., Fair, J. M., & Krauss, R. M. (1996) · Circulation · doi:10.1161/01.cir.94.9.2146 · Cited by 161
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions
de Ferranti, S. D., & Rifai, N. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00797-5 · Cited by 162
Behaviour of some indicators of oxidative stress in postmenopausal and fertile women
Signorelli, S. S., Neri, S., Sciacchitano, S., Pino, L. D., Costa, M. P., Marchese, G., Celotta, G., Cassibba, N., Pennisi, G., & Caschetto, S. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.03.001 · Cited by 163
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein
Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., Stier, U., & Forst, T. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.054 · Cited by 161
Cholesterol Profile Measurement by Vertical Auto Profile Method
Kulkarni, K. R. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.004 · Cited by 158
Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios.
Harwood, R., Sayer, A. A., & Hirschfeld, M. J. (2004) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862004000400006 · Cited by 159
Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin
Morand, O. H., Aebi, J. D., Dehmlow, H., Ji, Y., Gains, N., Lengsfeld, H., & Himber, J. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37449-6 · Cited by 159
Elasticity Imaging of Atheroma With Transcutaneous Ultrasound
Kanai, H., Hasegawa, H., Ichiki, M., Tezuka, F., & Koiwa, Y. (2003) · Circulation · doi:10.1161/01.cir.0000078633.31922.8a · Cited by 158
Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice
Gertz, K. R., Laufs, U., Lindauer, U., Nickenig, G., Böhm, M., Dirnagl, U., & Endres, M. (2003) · Stroke · doi:10.1161/01.str.0000054055.28435.bf · Cited by 155
New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy
Fedder, D. O., Koro, C. E., & L'Italien, G. J. (2002) · Circulation · doi:10.1161/hc0202.101971 · Cited by 158
Direct Vascular Effects of HMG-CoA Reductase Inhibitors
Laufs, U. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00044-x · Cited by 157
Cholesterol and the Risk of Ischemic Stroke
Bowman, T. S., Sesso, H. D., Ma, J., Kurth, T., Kase, C. S., Stampfer, M. J., & Gaziano, J. M. (2003) · Stroke · doi:10.1161/01.str.0000102171.91292.dc · Cited by 157
HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients
Mason, N. A., Bailie, G. R., Satayathum, S. S., Bragg‐Gresham, J. L., Akiba, T., Akizawa, T., Combe, C., Rayner, H. C., Saitō, A., Gillespie, B. W., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.09.025 · Cited by 158
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
Brown, W. V., Bays, H. E., Hassman, D. R., McKenney, J. M., Chitra, R., Hutchinson, H. G., & Miller, E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129312 · Cited by 156
Early vascular benefits of statin therapy
Tsiara, S., Elisaf, M., & Mikhailidis, D. P. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002225 · Cited by 157
Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
Brewer, H. B. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00308-2 · Cited by 158
A comparative study of the in vitro antioxidant activity of statins
Franzoni, F., Quiñones-Galvan, A., Regoli, F., Ferrannini, E., & Galetta, F. (2003) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00577-6 · Cited by 156
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Grinspoon, S. K., Fitch, K. V., Overton, E. T., Fichtenbaum, C. J., Zanni, M. V., Aberg, J. A., Malvestutto, C., Lu, M. T., Currier, J. S., Sponseller, C. A., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2018.12.016 · Cited by 161
Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation
Wong, B., Lumma, W. C., Smith, A. M., Sisko, J. T., Wright, S. D., & Cai, T. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.959 · Cited by 154
Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)
Arntz, H.-R., Agrawal, R., Wunderlich, W., Schnitzer, L., Stern, R., Fischer, F., & Schultheiß, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01230-3 · Cited by 158
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population
Pharoah, P. D. P., & Hollingworth, W. (1996) · BMJ · doi:10.1136/bmj.312.7044.1443 · Cited by 156
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 163
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Business cycles and mortality: results from Swedish microdata
Gerdtham, U., & Johannesson, M. (2004) · Social Science & Medicine · doi:10.1016/j.socscimed.2004.05.004 · Cited by 154
Atorvastatin
Malhotra, H. S., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161120-00012 · Cited by 153
Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts
Napoli, P. D. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00306-6 · Cited by 155
Safety and Efficacy of Long-Term Statin-Fibrate Combinations in Patients With Refractory Familial Combined Hyperlipidemia
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Didangelos, T., Carina, M., Kranitsas, D. F., & Kontopoulos, A. G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00430-x · Cited by 154
Hyperhomocysteinemia and Atherosclerotic Vascular Disease
Stein, J. H., & McBride, P. E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.12.1301 · Cited by 154
Periodontal therapy and cardiovascular risk
Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155
A Statin in the Treatment of Heart Failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): Study Design and Baseline Characteristics
KJEKSHUS, J. K., Dunselman, P., Blideskog, M., Eskilson, C., Hjalmarson, Å. C., McMurray, J. J. V., Waagstein, F., Wedel, H., Wessman, P., & Wikstrand, J. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.09.005 · Cited by 152
Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials
Brown, B. G., Stukovsky, K. H., & Zhao, X.-Q. (2006) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32800ff750 · Cited by 155
Relation Between Progression and Regression of Atherosclerotic Left Main Coronary Artery Disease and Serum Cholesterol Levels as Assessed With Serial Long-Term (≥12 Months) Follow-Up Intravascular Ultrasound
von Birgelen, C., Hartmann, M., Mintz, G. S., Baumgart, D., Schmermund, A., & Erbel, R. M. (2003) · Circulation · doi:10.1161/01.cir.0000103664.47406.49 · Cited by 154
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
Bays, H. E., Dujovne, C. A., McGovern, M. E., White, T. E., Kashyap, M. L., Hutcheson, A. G., & Crouse, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00007-9 · Cited by 154
Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events
van Lennep, J. E. R., Westerveld, H. T., van Lennep, H. W. O. R., Zwinderman, A. H., Erkelens, D. W., & van der Wall, E. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2408 · Cited by 152
Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
Chauvin, B., Drouot, S., Barrail‐Tran, A., & Taburet, A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0075-4 · Cited by 156
Concept and usefulness of cardiovascular risk profiles
Kannel, W. B., D’Agostino, R. B., SULLIVAN, L. M., & Wilson, P. W. F. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.022 · Cited by 151
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Chang, J. T., Staffa, J. A., Parks, M. A., & Green, L. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.977 · Cited by 152
Pathophysiology and clinical significance of atherosclerotic plaque rupture
Gutstein, D. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00322-8 · Cited by 151
Serum cholesterol concentration and death from suicide in men: Paris prospective study I
Zureik, M., Courbon, D., & Ducimetière, P. (1996) · BMJ · doi:10.1136/bmj.313.7058.649 · Cited by 151
Vascular effects of statins in stroke.
Delanty, N., & Vaughan, C. J. (1997) · Stroke · doi:10.1161/01.str.28.11.2315 · Cited by 163
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Tonelli, M. A., Lloyd, A., Clement, F., Conly, J. M., Husereau, D., Hemmelgarn, B. R., Klarenbach, S. W., McAlister, F. A., Wiebe, N., Manns, B., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.101280 · Cited by 153
A Systematic Review of the Effectiveness of Health Service Interventions Aimed at Reducing Inequalities in Health
Arblaster, L., Lambert, M., Entwistle, V., Forster, M., Fullerton, D., Sheldon, T., & Watt, I. (1996) · Journal of Health Services Research and Policy · doi:10.1177/135581969600100207 · Cited by 150
Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity
Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., & Mori, T. A. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.6.877 · Cited by 151
Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks
Voß, R., Cullen, P., Schulte, H., & Assmann, G. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.6.1253 · Cited by 148
Coronary Heart Disease in African Americans
Clark, L. T., Ferdinand, K. C., Flack, J. M., Gavin, J. R., Hall, W. D., Kumanyika, S., Reed, J. W., Saunders, E., Valantine, H. A., Watson, K. E., et al. (2001) · Heart Disease · doi:10.1097/00132580-200103000-00007 · Cited by 151
Screening for cardiovascular risk: public health imperative or matter for individual informed choice?
Marteau, T. M., & Kinmonth, A. L. (2002) · BMJ · doi:10.1136/bmj.325.7355.78 · Cited by 149
Venous thromboembolism associated with hip and knee replacement over a ten-year period
HOWIE, C. R., Hughes, H. C., & Watts, A. C. (2005) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.87b12.16298 · Cited by 149
Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?
Abeles, A. M., & Pillinger, M. H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21521 · Cited by 151
Serum Lipids and Incidence of Coronary Heart Disease
Frost, P. H., Davis, B. R., Burlando, A. J., Curb, J. D., Guthrie, G. P., Isaacsohn, J. L., Wassertheil-Smoller, S. W., Wilson, A. C., & Stamler, J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2381 · Cited by 147
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 153
Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease
Sadowitz, B. D., Maier, K. G., & Gahtan, V. (2010) · Vascular and Endovascular Surgery · doi:10.1177/1538574410362922 · Cited by 150
Current and Emerging Uses of Statins in Clinical Therapeutics: A Review
Davies, J. T., Delfino, S., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A., & Swanson, H. I. (2016) · Lipid Insights · doi:10.4137/lpi.s37450 · Cited by 156
Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus
Lemahieu, W. P. D., Hermann, M., Åsberg, A., Verbeke, K., Holdaas, H., Vanrenterghem, Y. F. C., & Maes, B. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01005.x · Cited by 149
Distribution of creatine kinase in the general population: Implications for statin therapy
Brewster, L. M., Mairuhu, G., Sturk, A., & van Montfrans, G. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.008 · Cited by 150
Interventions to improve adherence to lipid lowering medication
Schedlbauer, A., Davies, P. A., & Fahey, T. P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub3 · Cited by 152
The Effects of Metformin on Glycemic Control and Serum Lipids in Insulin-Treated NIDDM Patients With Suboptimal Metabolic Control
Robinson, A. C., Burke, J., Robinson, S., Johnston, D. G., & Elkeles, R. S. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.701 · Cited by 146
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials
Gould, A. L., Davies, G., Alemao, E., Yin, D., & Cook, J. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.05.012 · Cited by 147
Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to Benefit
Holmes, H. M., Min, L. C., Yee, M., Varadhan, R., Basran, J., Dale, W., & Boyd, C. M. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0095-7 · Cited by 151
Plant sterol ester–enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia
Amundsen, Å. L., Ose, L., Nenseter, M. S., & Ntanios, F. Y. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.338 · Cited by 147
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen, S. E., Menon, V., Nicholls, S. J., Brennan, D., Laffin, L., Ridker, P., Ray, K. K., Mason, D., Kastelein, J. J. P., Cho, L., et al. (2023) · JAMA · doi:10.1001/jama.2023.9696 · Cited by 146
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Perkovic, V., Johnson, D. W., Nigwekar, S. U., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005019.pub4 · Cited by 148
Lipid lowering effects of oyster mushroom (Pleurotus ostreatus) in humans
Schneider, I., Kressel, G., Meyer, A., Krings, U., Berger, R. G., & Hahn, A. (2010) · Journal of Functional Foods · doi:10.1016/j.jff.2010.11.004 · Cited by 148
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 153
Simvastatin Modulates Cytokine-Mediated Endothelial Cell Adhesion Molecule Induction: Involvement of an Inhibitory G Protein
Sadeghi, M. M., Collinge, M., Pardi, R., & Bender, J. R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2712 · Cited by 144
Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary prevention
Perreault, S., Blais, L., Lamarre, D., Dragomir, A., Berbiche, D., Lalonde, L., Laurier, C., St-Maurice, F., & Collin, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02355.x · Cited by 146
Obesity as the core of the metabolic syndrome and the management of coronary heart disease
Shirai, K. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003008 · Cited by 146
Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease
Grover, S. A., Paquet, S., Levinton, C. M., Coupal, L., & Zowall, H. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.655 · Cited by 146
Diabetes as a risk factor for myocardial infarction: population and gender perspectives
Lundberg, V., Stegmayr, B. G., Asplund, K., Eliasson, M., & Huhtasaari, F. (1997) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1997.tb00006.x · Cited by 146
Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel
Chodick, G., Shalev, V., Gerber, Y., Heymann, A. D., Silber, H., Simah, V., & Kokia, E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.012 · Cited by 145
Cardiovascular Risk Factors Predictive for Survival and Morbidity‐Free Survival in the Oldest‐Old Framingham Heart Study Participants
Terry, D. F., Pencina, M. J., Vasan, R. S., Murabito, J. M., Wolf, P. A., Kelly‐Hayes, M., Levy, D. A., D’Agostino, R. B., & Benjamin, E. J. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00465.x · Cited by 142
Intracranial Arteries of Human Fetuses Are More Resistant to Hypercholesterolemia-Induced Fatty Streak Formation Than Extracranial Arteries
Napoli, C., Witztum, J. L., de Nigris, F., Palumbo, G., D’Armiento, F. P., & Palinski, W. (1999) · Circulation · doi:10.1161/01.cir.99.15.2003 · Cited by 110
Low-density lipoproteins and risk for coronary artery disease
Ballantyne, C. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00769-3 · Cited by 145
Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo
Steiner, S., Speidl, W. S., Pleiner, J., Seidinger, D., Zorn, G., Kaun, C., Wojta, J., Huber, K., Minar, E., Wolzt, M., et al. (2005) · Circulation · doi:10.1161/01.cir.0000158665.27783.0c · Cited by 145
Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering
Margaritis, M., Channon, K. M., & Antoniades, C. A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5430 · Cited by 149
Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries
von Birgelen, C., Hartmann, M., Mintz, G. S., van Houwelingen, K. G., Deppermann, N., Schmermund, A., Böse, D., Eggebrecht, H., Neumann, T., Gössl, M., et al. (2004) · Circulation · doi:10.1161/01.cir.0000142048.94084.ca · Cited by 144
Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials
Reriani, M., Dunlay, S. M., Gupta, B. P., West, C. P., Rihal, C. S., Lerman, L. O., & Lerman, A. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711398430 · Cited by 145
Statin use and the risk of developing diabetes: a network meta‐analysis
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4020 · Cited by 147
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model
Ferrara, D. E., Liu, X., Espinola, R. G., Meroni, P. L., Abukhalaf, I. K., Harris, E. N., & Pierangeli, S. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11449 · Cited by 143

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks